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Using the nonaccelerated murine nephrotoxic nephritis (NTN) as a model of chronic kidney disease (CKD) could provide an
easily inducible model that enables a rapid test of treatments. Originally, the NTN model was developed as an acute model of
glomerulonephritis, but in this study we evaluate the model as a CKD model and compare CD1 and C57BL/6 female and male
mice. CD1 mice have previously showed an increased susceptibility to CKD in other CKD models. NTN was induced by injecting
nephrotoxic serum (NTS) and evaluated by CKD parameters including albuminuria, glomerular filtration rate (GFR), mesangial
expansion, and renal fibrosis. Both strains showed significant albuminuria on days 2-3 which remained significant until the last
time point on days 36-37 supporting dysfunctional filtration also observed by a significantly declined GFR on days 5-6, 15–17, and
34–37. Both strains showed early progressive mesangial expansion and significant renal fibrosis within three weeks suggesting CKD
development. CD1 and C57BL/6 females showed a similar disease progression, but female mice seemed more susceptible to NTS
compared to male mice.The presence of albuminuria, GFR decline, mesangial expansion, and fibrosis showed that the NTNmodel
is a relevant CKD model both in C57BL/6 and in CD1 mice.
1. Introduction
Animal models with clinical and pathological features of
human chronic kidney disease (CKD) are highlywarranted to
advance novel therapies for CKD and would enable a deeper
understanding of the pathogenesis and thereby more target-
specific therapies. CKD is defined clinically by prolonged and
progressive loss of kidney function measured by a declined
glomerular filtration rate (GFR) and the presence of albu-
minuria with pathological findings of mesangial expansion,
inflammation, and renal fibrosis [1].
Prior work has documented limitations of the clas-
sical murine models of CKD including the unilateral
ureteral obstruction (UUO), 5/6 nephrectomy, and diabetic
nephropathy models [2, 3]. The pathogenesis of the UUO
and the 5/6 nephrectomy models is difficult to study. The
unobstructed kidney in the UUO model compensates for
the loss of function in the obstructed kidney [2]. In the 5/6
nephrectomy model, only a small amount of kidney tissue is
available, and the model requires a difficult technical surgery
making it difficult to reproduce [3–6]. Models of diabetic
nephropathy also have their limitations as both the classical
streptozotocin- (STZ-) induced model and the db/db model
develop slowly and often only show mild signs of CKD [7].
The pathogenesis in the nonaccelerated nephrotoxic
nephritis (NTN) model is initiated by anti-glomerular IgGs
that impair the glomerular filtration barrier and induce
proteinuria and inflammation. The NTN model is largely
described as a model of acute glomerulonephritis, and the
knowledge of the long-term pathogenesis and strain differ-
ences in the nonaccelerated murine NTN model is therefore
limited [3, 8–10]. The standard of care for CKD has for many
decades consisted of treatment with angiotensin-converting-
enzyme inhibitors (ACE-I’s) or angiotensin receptor blockers
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Figure 1: Study set up in C57BL/6 and CD1 mice.
that reduce albuminuria and slow down the disease progres-
sion [11]. A previous study in the NTN rat has demonstrated
that ACE-Is reduce albuminuria and glomerular sclerosis
indicating theNTNmodel is a suitablemodel of humanCKD
[12].
The murine C57BL/6 strain is the most commonly used
genetic background of inbred strains in research. However,
these strains are resistant to the development of CKD in
the standard model; 5/6 nephrectomy unless hypertension
is induced in addition [13]. Furthermore, the nephrectomy
and the streptozotocin models show increased CKD severity
in the outbred stock—CD1—compared to the C57BL/6 mice
[14–16]. The influence of gender on CKD is still debated.
However, the prevalence of CKD tends to be increased in
women, but the CKD is more severe in men [17].
The murine model of NTN allows investigations of
the immune mechanisms in rapidly progressive glomeru-
lonephritis (GN). Few chronic experiments have evaluated
the more chronic features of the induced kidney damage
by testing therapeutic strategies for renal fibrosis in the
accelerated NTN model with the use of immunisation and
adjuvants [18, 19]. Therefore, we performed an in-depth time
course study using both C57BL/6 and CD1 male and female
mice in the nonaccelerated NTN model by measuring their
acute and progressive chronic manifestations of CKD.
2. Materials and Methods
2.1. Experimental Animals and Study Design. C57BL/6 mice
(8–10 weeks) were purchased from Taconic (Ry, Denmark)
and CD1 mice (8–10 weeks) were purchased from Charles
River (Germany). The mice were housed in a facility with a
12 h light/dark cycle with free access to water and Altromin
chow. Before the study, the mice were acclimatised for one
week. All animal experiments were approved by the Danish
Animal Inspectorate and the Novo Nordisk ethical review
board. Mice were euthanised if they experienced >20%
weight loss or compromised health.
Prior to termination, mice were induced with isoflurane,
and the kidneys were perfused with 0.9% NaCl with Heparin
(10U/ml) before isolation and collection.
Initial dose titration studies were conducted to determine
the optimal dose of NTS in both strains using 50–250 𝜇l of
NTS. The optimal doses were used in two parallel experi-
ments conducted in C57BL/6 and CD1 mice to determine
the time course of CKD disease development. Nonaccel-
erated NTN was induced by a single tail-vein injection of
250 𝜇l (C57BL/6) and 100 𝜇l (CD1) of sheep anti-rat NTS
(Probetex, San Antonio, USA, PTX-001S lot#199-8). Control
mice received PBS by same administration and volume.
The study design followed a randomised block design with
30 mice in each group. At days 7, 21, and 42 ten mice
per group were sacrificed, and plasma and kidneys were
collected (Figure 1). The mice were weighed on day 0 just
before NTS was injected and hereafter twice a week, and
the percentage weight change was calculated throughout the
study. The gender studies in CD1 and C57BL/6 are described
in supplementary materials.
2.2. Urine and Plasma Analysis. Urine was collected by
metabolic caging to measure the urinary albumin concen-
tration and to calculate the urinary albumin excretion rate
(UAER). Mice were single-housed in metabolic cages for 18
hours on days 2-3, 6-7, 16-17, and 36-37. Urinary markers
were measured by ELISA: albumin (Bethyl Laboratories,
cat.no. E90-134), Cystatin C (R&D systems, Minneapolis,
MN Cat. number MSCTCO) and TNFR1 (R&D systems,
Minneapolis MN Cat. number MRT10). Urinary creatinine
was measured by high-performance liquid chromatography
(HPLC). Creatinine was measured in serum by acetoni-
trile deproteinization, followed by isocratic, cation exchange
HPLC as previously described [20].
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Blood plasma was prepared from blood samples collected
on days 7, 14, 21, 28, and 42. Serum Amyloid P (SAP) was
measured by ELISA (Genway, SanDiego, CA). CystatinCwas
measured using ELISA (R&D systems,Minneapolis,MNCat.
number MSCTCO).
2.3. Glomerular Filtration Rate. Theglomerular filtration rate
(GFR) was measured in CD1 female mice (8–10 weeks) in
an additional study with similar induction of NTN. The
glomerular filtration rate (GFR) was measured on days 5-6,
15–17, and 34–37 by preclinical transdermal GFR monitors
(Medibeacon GmBH, Mannheim, Germany) as previously
described [21]. In short, a square of 2 × 2 centimetres fur
on the back of the mice were depilated 24 hours prior to
GFR measurements. A stock of FITC-sinistrin (Medibeacon
GmBH, Mannheim, Germany) was prepared and stored in
aliquots at −20∘C. Prior to injection of FITC-sinistrin, the
mice were lightly anaesthetised and the GFR monitor was
adhered to the depilated area by adhesive tape.Themice were
injected intravenously in the tail vein with 7.5mg/100 g BWof
FITC-sinistrin and placed in an enriched cage for one hour.
2.4. Kidney Gene Expression by Real-Time Quantitative PCR.
Following euthanasia, one-half of the left kidney was snap
frozen in liquid nitrogen and stored at −80∘C. Frozen kid-
ney tissue was homogenised in Qiazol reagent, RNA was
isolated using the RNAeasy Mini kit as described by the
suppliers (Qiagen, Mississauga, ON, Canada) and cDNA was
generated using SuperScript VILO cDNA Synthesis kit (Life
Technologies, Burlington, ON, Canada). Afterwards Real-
Time Quantitative PCR (RT qPCR) was performed with
Gene Expression Master Mix (Life Technologies) using a
7900HT Fast Real-Time PCR System. Specific gene expres-
sion was measured with the following Taqman assays (Life
Technologies): C3 (Mm01232779 m1, C3), procollagen 3a1,
(Mm01254476 m1, Col3a1), Fibronectin (Mm01256744 m1,
Fn1), and PAI-1 (Mm00435858 m1, Serpine1). RT qPCR
was performed in triplicate, and the values normalised to
GAPDH and RPL27 as previously described [22].
2.5. Histological Analysis. Perfused kidneys were fixed in 4%
paraformaldehyde for 30 h, processed by standard procedures
through graded concentrations of alcohol and xylene and
embedded in paraffin. Paraffin sections of 3 microns were
stained with Periodic Acid-Schiff (PAS) and scanned using
the Nanozoomer 2.0 (Hamamatsu Photonics K.K., Hama-
matsu, Japan) at a magnification of ×40. The mesangial
expansion was evaluated in a blinded fashion as 20 glomeruli
of each kidney were assessed and graded into four categories:
0 (no mesangial expansion), 1 (mild mesangial expansion,
mesangial matrix wide < 2 nucleus diameter), 2 (moderate
mesangial expansion, mesangial matrix wide < 4 nucleus
diameter), and 3 (severe mesangial expansion, > 4 nucleus
diameter).The 20 glomeruli of eachmousewere evaluated for
metaplasia, segmental or global sclerosis. Furthermore, the
kidneys were evaluated for the presence of protein casts. The
tubular casts were visualised as solidification of protein in the
lumen of the kidney tubules. The metaplasia was visualised
as a change from flattened parietal epithelium to cuboidal
epithelium lining the glomerulus. The segmental glomeru-
losclerosiswas visualised as glomeruli that showed scarring of
small sections of the glomeruli, while global glomeruloscle-
rosis was visualised as totally scarred glomeruli.
2.6. Immunohistochemistry. Immunohistochemical (IHC)
staining of collagen III was performed to quantitate renal
fibrosis. Paraffin-embedded sections were deparaffinised
and hydrated followed by antigen retrieval with proteinase
K (10 𝜇g/ml) treatment for 10 minutes at 37∘C and treated
in TBS for 5 minutes. Endogenous peroxidase was blocked
using 0.5% H2O2 in TBS for 20 minutes, and sections were
incubated with avidin and biotin for 10min each. Sections
were incubated with TBS mixed with 7% donkey, 3% mouse
serum, and 3% skimmed milk. Subsequently, sections
were incubated overnight at 4∘C with goat anticollagen
III (Southern Biotech, Birmingham, USA) diluted in 7%
donkey, 3% mouse serum, and 0.5% skimmed milk in TBS.
The next day, the sections were incubated in biotinylated
donkey anti-goat IgG (cat. number 705-065-147) diluted
in 7% donkey, 3% mouse serum, and 0.5% skimmed milk
in TBS and afterwards in vectastain ABC complex in TBS.
Specific binding of antibodies was visualised by enzymatic
conversion of the chromogenic substrate DAB into a brown
precipitate by HRP activated by hydrogen peroxide. The
slides were counterstained with haematoxylin.
2.7. Digital Image Analysis for Quantification of Fibrosis.
All slides were scanned using the Nanozoomer 2.0 at an
original magnification of ×40. The image analysis was per-
formed using Visiopharm Integrator System software (VIS;
Visiopharm, Hoersholm, Denmark). An automated tissue
detection protocol was performed as previously published
[23]. Evaluation of the collagen III staining was determined
in a region of interest (ROI) restricted to the cortex region.
Within the ROI a threshold (∞–70) analysis was performed
using HDAB-DAB channel as previously published [23].
2.8. Statistics. Statistical analyses were performed using
GraphPad Prism (v6.5; GraphPad Software, CA), and data
were presented as the mean ± standard deviation (SD).
D’Agistino-Pearson normality test was performed. Normally
distributed data were analysed by one-way ANOVA mul-
tiple testing with Turkey’s correction, and nonnormally
distributed data were analysed using Kruskal-Wallis multi-
ple testing with Dunn’s correction. Two-way ANOVA was
applied for comparing CD1 and C57BL/6 mice at different
time points. A 𝑃 value < 0.05 was accepted as statistically
significant.
3. Results
3.1. CD1 Mice Display Increased Susceptibility to NTS Com-
pared to C57BL/6 Mice. The initial dose titration studies
showed that mice subjected to NTS developed albuminuria
in a dose-dependent manner in both CD1 mice (Figure 2(a))
and C57BL/6 mice (Figure 2(b)). C57BL/6 mice subjected to
250 𝜇l NTS showed an increased urinary albumin excretion
rate (UAER) on days 9/10 compared to the groups subjected
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Figure 3: NTS induces significant and chronic increase in UAER and urine albumin concentration. (a) Scatter plot showing the 24 h urinary
albumin excretion rate (UAER) on days 2-3, 6-7, 16-17, and 36-37. (b) Scatter plot showing urinary albumin concentration on days 2-3, 6-7,
16-17, and 36-37. Data are shown as mean ± SD. #𝑃 < 0.0001 NTN groups versus PBS groups and 𝛿𝑃 < 0.05, 𝛿𝛿𝛿𝛿𝑃 < 0.0001 CD1 NTN versus
B6 NTN groups by two-way ANOVA (𝑛 = 10).
to 25 or 100 𝜇l NTS (Figure 2(b)). The dose of 250 𝜇l NTS
severely affected the welfare of the CD1 mice, and 65%
of this group were euthanised shortly after study initiation
due to severe weight loss and signs of compromised health.
A gross pathological evaluation showed that these mice
had severe glomerulonephritis, and consequently, this group
was excluded. CD1 mice subjected to 100 𝜇l NTS showed
an increased UAER on days 16/17 compared to the group
subjected to 50 𝜇l NTS (Figure 2(a)).
Based on these results, 250 𝜇l and 100 𝜇l NTS were
selected for subsequent experiments in C57BL/6 and CD1,
respectively.
3.2. NTS Induces Albuminuria, GFR Decline, and Transient
Weight Loss. NTN induction in both strains resulted in sig-
nificantly increased UAER compared to the healthy controls
on days 2-3, 6-7, 16-17, and 36-37 after NTS injection (Fig-
ure 3(a)). Furthermore, the albumin concentrations of the
NTN urine samples were significantly increased compared
to the control urine samples at all-time points (Figure 3(b)).
The CD1 NTNmice developed significantly increased UAER
on days 2-3, 6-7, and 16-17 compared to C57BL/6 NTN mice
(Figure 3(a)). No difference in UAER was observed between
C57BL/6 male and female mice, but the female NTN mice
showed a trend towards increased UAER (𝑃 = 0.0708 at
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#
𝑃 < 0.05 CD1 NTN versus CD1 PBS by one-way ANOVA (𝑛 = 10); 𝛿𝛿𝛿𝛿𝑃 < 0.0001 CD1 NTN versus B6 NTN groups by two-way ANOVA
(𝑛 = 10).
6 weeks and 𝑃 = 0.0746 at 10 weeks, data not shown).
However, CD1 NTN female mice developed significantly
increased UAER compared to male NTN mice on days 35-
36 (Supplementary material, Figure 1). The urinary albumin
creatinine ratio (UACR) showed similar temporal dynamics
as the UAER. The UACR peaked on days 6-7 and 2-3 in
CD1 and C57BL/6 NTNmice, respectively (Figure 4(a)). The
NTN induction caused a significant decrease in GFR on days
5-6, 15–17, and 34–37 in CD NTN mice compared to their
controls. NTS induced transient body weight loss from day
one until day 6; C57BL/6 NTN mice showed significantly
greater weight loss (mean: −16,9%) compared to the CD1
NTNmice (mean: −6,3%). However, both CD1 and C57BL/6
NTN mice recovered to their initial body weight within 20
days and gained weight throughout the study (Figure 4(c)).
3.3. NTS Induces Significant Urinary Excretion of Cystatin C
and Tumour Necrosis Factor Receptor 1. The urine analysis
showed that the 24-hour urinary Cystatin C excretion was
significantly increased on days 2-3, 6-7, and 16-17 in CD1
NTN mice and on days 2-3 and 6-7 in C57BL/6 NTN mice
compared to control mice (Figure 5(a)). The 24-hour urinary
excretion of tumour necrosis factor receptor 1 (TNFR1) was
also significantly increased on days 2-3, 6-7, 16-17, and 36-37
in both strains (Figure 5(b)).
3.4. NTS Induces Systemic Inflammation and Elevation of a
GFR Marker. The plasma levels, of the acute phase protein
SAP, were significantly increased on day 7 in C57BL/6
mice and days 7 and 14 in CD1 mice injected with NTS
(Figure 6(a)). Supporting this notion, Cystatin C, a marker
6 International Journal of Nephrology
10
100
1000
10000
100000
Days 2-3 Days 6-7 Days 16-17 Days 36-37
#
# # #
#
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
U
rin
ar
y 
Cy
s C
 ex
cr
et
io
n 
(n
g/
24
hr
s)
(a)
0.01
0.1
1
10
100
Days 2-3 Days 6-7 Days 16-17 Days 36-37
#
#
# #
#
#
#
#
U
rin
ar
y 
TN
FR
1 
ex
cr
et
io
n 
(n
g/
24
hr
s)
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
(b)
Figure 5: NTS induces significant urinary excretion of Cystatin C and TNFR1. (a) Scatter plot showing the 24 h urinary Cystatin C excretion
rate over timemeasured by ELISA. (b) Scatter plot showing 24 h urinary TNFR1 excretion rate over timemeasured by ELISA. Data are shown
as mean ± SD. #𝑃 < 0.01 NTN groups versus PBS groups by two-way ANOVA (𝑛 = 10).
of inflammation and GFR, was also significantly increased
on days 7 and 14 in both C57BL/6 and CD1 following NTS.
In addition, Cystatin C was also significantly increased on
days 21, 28, and 42 in both strains compared to control mice
(Figure 6(b)). The inflammatory response was further inves-
tigated by complement involvement by looking at mRNA
levels of C3. NTN induction significantly increased C3 gene
expression in both strains on days 7, 21, and 42 (Figure 6(c)).
3.5. NTS Induces Chronic Kidney Injury with Mesangial
Expansion and Renal Fibrosis. Themesangial expansion was
observed in both CD1 and C57BL/6 NTN mice on days 7,
21, and 42 compared to their healthy controls (Figures 7(a)
and 7(b)). The glomerular mesangial expansion progressed
over time as it significantly increased from days 7 to 21
and from days 21 to 42 in both strains (Figure 7(b)). Both
strains showed 20–22% segmentally sclerosed glomeruli on
days 7, 21, and 42 and developed increased globally sclerosed
glomeruli over time (2% on day 7 and 13% on day 42
(Table 1)). In addition, both strains developed metaplasia
in 24–29% of the assessed glomeruli on days 7, 21, and 42.
Tubular casts within cortex were present at all-time points
(Table 1).
Moreover, hypercellular glomeruli, tubular prolifera-
tion, and dilatation were observed together with increasing
immune cells accumulating in the tubulointerstitium and
infiltrating the periglomerular space surrounding glomeruli.
NTS induced similar significantly increased collagen
III accumulation, and thereby renal fibrosis was observed
already on day 21 in both strains (Figures 8(a) and 8(b))
compared to healthy controls. Renal fibrosis remained sig-
nificantly increased on day 42 compared to controls, but
it did not progress from day 21 (Figure 8(b)). No differ-
ence in collagen III accumulation was observed between
C57BL/6 male and female NTN mice. However, only the
female C57BL/6 NTNmice developed significantly increased
collagen III deposition compared to their healthy controls
(Supplementary Material, Figure 2). The female NTN mice
developed significantly increased collagen III deposition
compared to male CD1 NTN mice (Supplementary Material,
Figure 1).
To further investigate the development of kidney fibrosis
andmatrix remodeling, mRNA levels of collagen type III (col
III), fibronectin (fn1), and PAI-1 (Serpine1) were quantified.
The NTN induction significantly increased the mRNA levels
of collagen type III and PAI-1 in CD1 mice on days 7, 21, and
42 and in C57BL/6mice on days 7 and 42 (Figures 8(c)–8(e)).
The fibronectin mRNA levels were significantly increased in
CD1 NTN mice on days 7 and 21 and in C57BL/6 mice on
day 7 compared to control mice. In general, the CD1 female
NTNmice showed increased mRNA levels on the profibrotic
genes compared to C57BL/6 NTN mice, and in addition,
C57BL/6 female NTNmice developed significantly increased
collagen III mRNA levels compared to C57BL/6 male NTN
mice (Supplementary Material, Figure 2).
4. Discussion
The nonaccelerated NTN model is a widely used model of
acute GN, but no characterisation of the chronic progression
of the disease is thoroughly described in mice. The nonac-
celerated NTN model has previously been characterised in
the rat, where NTN induces an autologous (acute) phase
characterised by inflammation and severe proteinuria and a
heterogeneous (chronic) phase characterised by glomerular
lesions [24–26]. In this study we show that NTS injection in
bothCD1 andC57BL/6mice induced not only an acute phase,
as previously described, but also several hallmarks of CKD
including albuminuria, GFR decline, mesangial expansion,
inflammation, and renal fibrosis which were significantly
present in the later stages of the inducedNTS kidney damage.
The NTS induction significantly increased albuminuria,
already on days 2-3 in both CD1 and C57BL/6 mice, sug-
gesting an acute leakage of protein as soon as anti-GBM
antibodies are deposited. The mean albuminuria declined
around days 16-17, but significant elevation in UAER and
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Figure 6: NTS induces systemic inflammation and elevation of GFR marker. (a) Scatter plot showing the SAP plasma concentration on days
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urine albumin concentration remained at days 36-37 in both
strains at approximately 2 logs above controls. At days 36-
37 the ACR were still in the range of 33–43mg/mg which
is above the observed ACR of CKD models such as renal
ablation models, UUO, and the STZ model supporting that
the NTN model is a potential CKD model [27–29].
Decreased GFR is a hallmark of CKD and GFR is
estimated or measured in patients for confirming diagnosis
[30]. Thus, the observed GFR decline on days 5-6, 15–17,
and 34–37 demonstrates that the NTN model resembles
features of human CKD. The significantly increased urinary
albumin concentration, UACR, UAER, and the GFR decline
point towards glomerular impairment and thereby kidney
dysfunction in the NTN mice [31]. Furthermore, the sig-
nificant urinary excretion of Cystatin C indicates that NTN
induction causes tubular dysfunction. Cystatin C is freely
filtered by the glomerulus and is in healthy individuals almost
100% reabsorbed by the tubules and catabolised. On days
36-37 the urinary Cystatin C excretion in the NTN mice
had returned to baseline levels which might be explained by
increased reabsorption of the remaining functional nephrons
or a resolution of the tubules.
The increased urinary excretion of TNFR1 might be
explained by the phenomenon of shedding the receptors
frommembranes of TNF-𝛼 activated glomerular and tubular
cells by a proteolytic process where the TNF-alpha convert-
ing enzyme (TACE) cleaves TNFR1 as an immunological
response. On the other hand, Bemelmans et al. suggested
that a continuous release of soluble TNFR1 occurs and the
kidney clears it in healthy individuals [32]. The consistent
levels of urinary TNFR1 excretion in the controlmice support
the hypothesis of a continuous release of TNFR1, and the
significantly increased UAER at all-time points indicates a
dysfunctional filtration barrier as both TNFR1 and albumin
in healthy individuals are blocked by the glomerular filtration
barrier by size and charge selectivity [33–35].
The pathological characterisation of human CKD is
defined as the presence of kidney damage that progresses
or remains over time and includes, in general, glomerular
lesions and renal fibrosis [36–38]. The NTN model shows
the presence of chronically progressing kidney damage
detected by significant impairment of mesangial expansion
and increased globally sclerosed glomeruli between each time
point in both strains. Furthermore, the significant mesangial
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Figure 7:NTS causes chronic and progressive glomerular mesangial expansion in C57BL/6 and CD1mice. (a) Representative glomeruli showing
scores 0, 1, 2, and 3 of mesangial expansion. (b) Scatter plot showing the mean glomerular mesangial expansion (ME) score on days 7, 21, and
42. Data are shown as mean ± SD. #𝑃 < 0.0001 NTN groups versus PBS groups; ∗∗∗𝑃 < 0.001 NTN group day 7 versus NTN group day 21;
∗∗∗∗
𝑃 < 0.0001 NTN group day 21 versus NTN group day 42 by two-way ANOVA and using Kruskal-Wallis multiple testing (𝑛 = 10).
expansion on day 7 indicates a fast disease development.
The progressive mesangial expansion developing on day 42
shows that theNTS causes features of chronic and progressive
disease development.
In human CKD, renal fibrosis is characterised by
the deposition of extracellular matrix (ECM) components
including collagen III and fibronectin [39]. During patho-
logical conditions, PAI-1 contributes to the accumulation
of ECM components as PAI-1 inhibits degradation of ECM
proteins [39]. NTS induced significant renal fibrosis detected
by collagen III deposition on day 21 and day 42 in both strains.
However, in contrast to the mesangial expansion, the renal
fibrosis did not progress from day 21, suggesting that the
fibrotic response observed here could be linked to the resolu-
tion of the initial inflammatory reaction in the NTN model.
Interestingly, the development of renal fibrosis was somewhat
similar inCD1 andC57BL/6mice, which contradicts previous
studies describing CD1 mice with an increased susceptibility
to renal fibrosis in the 5/6 nephrectomy and STZ models
[13, 15, 16]. However, differences inmodel duration and insult
could be the explanation.
The significantly increased mRNA levels of collagen III,
fibronectin, and PAI-1 in both strains were reduced on day
42 compared to day 7 suggesting a continued but slowed
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Table 1: Histopathological lesions by mouse strains. The tubular casts were visualised as solidification of protein in the lumen of the
kidney tubules. The metaplasia was visualised as a change from flattened parietal epithelium to cuboidal epithelium lining the glomerulus.
The segmental glomerulosclerosis was visualised as glomeruli that showed scarring of small sections of the glomeruli, while global
glomerulosclerosis was visualised as totally scarred glomeruli.
Pathologic changes
NTN mice
CD1 day 7
𝑛 = 9
% B6 day 7
𝑛 = 6
% CD1 day 21
𝑛 = 10
% B6 day 21
𝑛 = 6
% CD1 day 42
𝑛 = 8
% B6 day 42
𝑛 = 7
%
Tubular casts (cortex)
Present (yes/no) 9 100 6 100 9 90 6 100 7 86 6 86
Metaplasia
47 26 35 29 54 27 32 27 38 24 33 24
Glomerulosclerosis (segmental)
39 22 24 20 44 22 25 21 35 22 20 14
Glomerulosclerosis (global)
4 2 2 2 22 11 8 7 20 13 18 13
profibrotic activity which correlates with the discontinued
progression of collagen III depositions from day 21.
Immune system activation and inflammation play a cen-
tral role in the pathogenesis of acute kidney injury and CKD
[40]. Following NTS injection both CD1 and C57BL/6 mice
developed an acute phase inflammatory response evaluated
by significantly elevated SAP in plasma on days 7–14. The
baseline SAP levels of CD1 mice were significantly higher
compared to C57BL/6 mice, which is consistent with litera-
ture describing strain differences in baseline SAP levels [41].
Cystatin C is described as being elevated during systemic
inflammation [42], which could account for the elevation
observed on days 7 and 14 consistently with the elevated
plasma SAP. However, Cystatin C is not only increased due
to inflammation as several studies describe Cystatin C as a
superior marker of GFR [43, 44]. The observed decline in
GFR on days 5-6, 15–17, and 34–37 in CD1NTNmice strongly
suggests that the increase in Cystatin C levels observed on
days 7 and 14 is caused both by inflammation and by a decline
in renal function. It is very likely that the elevated Cystatin C
after day 14 is mainly a response to the declined GFR.
Activation of the complement system by immune com-
plexes is known to occur in immune-mediated CKDs [45].
Complement 3 is synthesised by glomerular cells, and tubular
cells and the local synthesised C3 has been demonstrated to
play a role in the development of kidney disease [45, 46].
The upregulation of C3 mRNA levels in the NTN mice
suggests that the injected anti-GBM antibodies activate the
complement system which is in agreement with literature
describing this phenomenon in the NTN model [47].
NTS induced a transient weight loss in both the CD1 and
C57BL/6 NTN mice. The weight loss could be a response to
NTS induced illness causing decreased diet and fluid intake.
However, the recovered body weight after around day 10
indicates that the NTS doses are tolerated.
Comparing the nonacceleratedNTNmodel to otherCKD
models, the NTN model displays a technically easy and
consistently inducible model with rapid disease progression
when the optimal NTS dose is identified.We have shown that
NTN mice develop a chronic stage of kidney disease within
21 days as seen by glomerulosclerosis, fibrosis, inflammation,
tubular damage, elevated systemicmarkers of kidney damage,
and albuminuria, whereas, for example, classical diabetic
nephropathymodels developmild signs of CKDwithin 15–18
weeks [7]. The NTN model displays morphological aspects
as mesangial expansion as well as inflammatory and fibrotic
responses. In contrast, the widely used UUO model which
also develops rapid inflammation and renal fibrosis is limited
by the unobstructed kidney compensating for the obstructed
kidney making it impractical to study the pathogenesis [2].
The 5/6 nephrectomymodel develops glomeruli sclerosis and
renal fibrosis within 12 weeks, but it requires a technically
difficult surgery making it difficult to reproduce [6, 48].
The inbred C57BL/6 and outbred CD1 mice showed sim-
ilar kidney disease progression. However, the CD1 mice had
significantly increased UAER andmRNA levels of profibrotic
genes at several time points compared to C57BL/6 mice. In
addition, the strains showed different susceptibility to NTS
as the doses needed to induce similar kidney damage were
100 and 250𝜇l NTS, respectively. At present this difference is
not well understood but is possibly related to their different
genetic background, which could result in different binding
properties of anti-GBM antibodies, different inflammatory
response to antibody deposition, or different reactivity to
other sheep serum components in the two strains. The
C57Bl/6 mice showed only mild gender differences based
on the significantly increased collagen III mRNA levels
observed in NTN females compared to NTN males in week
10. Conversely, the CD1 NTN females showed significant
UAER on days 35-36 and significantly increased collagen III
deposition compared to NTN males indicating that the CD1
females are more susceptible to NTS compared to CD1males.
In conclusion, we have shown that the nonaccelerated
NTNmodel in addition to acute inflammatory kidney disease
develops several chronic hallmarks of CKD such as albu-
minuria, GFR decline, progressive mesangial expansion, and
renal fibrosis. C57BL/6 and CD1 mice showed similar disease
manifestations making them both applicable to studies of
the acute and chronic phases of kidney disease using the
nonaccelerated NTN model. The CD1 mice did not display
increased susceptibility to develop renal fibrosis as described
in other CKD models. However, the CD1 mice, especially
10 International Journal of Nephrology
Day 7 Day 21 Day 42
C5
7B
L/
6
CD
1
Control NTN Control ControlNTN NTN
250 －
250 －
(a)
0
2
4
6
8
%
 C
ol
la
ge
n 
II
I p
os
iti
ve
 p
r c
or
te
x 
ar
ea
Day 7 Day 21 Day 42
#
#
#
#
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
∗∗∗
∗∗∗∗
(b)
0
5
10
15
C
ol
la
ge
n 
II
I m
RN
A
 (f
ol
d 
ch
an
ge
)
Day 7 Day 21 Day 42
#
#
#

 #
 #
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
(c)
0
5
10
Fn
1 
m
RN
A
 (f
ol
d 
ch
an
ge
)
Day 7 Day 21 Day 42
#
# #
#
#
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
(d)
0
5
10
15
20
PA
I-
1 
m
RN
A
 (f
ol
d 
ch
an
ge
)
Day 7 Day 21 Day 42
#
#
#
 #
#
CD1 NTN
CD1 PBS
C57BL/6 NTN
C57BL/6 PBS
(e)
Figure 8: NTS induces chronic renal fibrosis. (a) Representative images of tubulointerstitial fibrotic area visualised by immunohistochemical
collagen III staining. (b) Semiquantification of collagen III positive area of the cortex area. (c) Scatter plot showing mRNA expression in
whole kidney tissue of Col3a1 as fold change. (d) Fibronectin (Fn1) mRNA expression as fold change. (e) PAI-1 (Serpine-1) mRNA expression
as fold change. Data are shown as mean ± SD. #𝑃 < 0.0001 NTN groups versus PBS groups; ∗∗∗𝑃 < 0.001 NTN day 7 versus NTN day 21;
∗∗∗∗
𝑃 < 0.0001 NTN day 7 versus NTN day 21; and 𝛿𝛿𝑃 < 0.01, 𝛿𝛿𝛿𝛿𝑃 < 0.0001 CD1 NTN versus B6 NTN groups by two-way ANOVA
(𝑛 = 10).
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the CD1 female mice, did show a higher susceptibility to
NTS which would possibly make them the more practical
choice. The nonaccelerated NTN model quickly resembles
hallmarks of acute and chronic CKD and its robustness
and relatively simple NTS induction phase make it a valid
alternative compared to other cumbersome models of CKD.
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